16 / 17
Page 54
conferenceseries
.com
Volume 10
Journal of Cancer Science & Therapy
Cancer Summit 2018
July 02-03, 2018
July 02-03, 2018 Bangkok, Thailand
World Cancer Summit 2018
Delving KS-01 as a novel therapeutic strategy in treating breast cancer.
Sourav Taru Saha
Department of Biochemistry, University of the Witwatersrand, Johannesburg, South Africa.
C
ancer cells have an increased need for cholesterol, which is required for cell membrane integrity. Cholesterol accumulation
has been described in various malignancies including breast cancer. Cholesterol has also been known to be the precursor
of estrogen and vitamin D, both of which play a key role in the histology of breast cancer. Thus, depleting the cholesterol
levels in cancer cells is a proposed innovative strategy to treat cancer. Therefore, novel cholesterol-depleting compounds are
currently being investigated. KS-01 is a cyclic amylose oligomer composed of glucose units. It solubilizes the cholesterol and
is proven to be toxicologically benign in humans. This led us to hypothesize that it might deplete cholesterol from cancer
cells and may prove to be a clinically useful compound. Our work provides preliminary experimental evidences to support
this hypothesis. We identified the potency of KS-01
in vitro
against two breast cancer cell lines: MCF-7 (Estrogen positive,
ER+), MDA-MB-231(Estrogen negative, ER-) and compared the results against two normal cell lines: MRC-5 (Normal Human
Lung Fibroblasts) and HEK-293 (Normal human embryonic kidney cells) using cytotoxic, apoptosis and cholesterol based
assays. KS-01 treatment reduced intracellular cholesterol resulting in significant breast cancer cell growth inhibition through
apoptosis. The results hold true for both ER+ and ER-. These data suggest that KS-01 can prevent cholesterol accumulation in
breast cancer cells and is a promising new anticancer agent.
1575707@students.wits.ac.zaJ Cancer Sci Ther 2018, Volume 10
DOI: 10.4172/1948-5956-C5-136